

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Estimated average burden  
 hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>Ferola Peter</b>			2. Issuer Name and Ticker or Trading Symbol <b>BIOTELEMETRY, INC. [ BEAT ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>SVP &amp; General Counsel</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>09/04/2019</b>					
1000 CEDAR HOLLOW RD. SUITE 102			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street) <b>MALVERN PA 19355</b>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/04/2019		M		6,835	A	\$8.68	19,622	D	
Common Stock	09/04/2019		M		17,751	A	\$10.36	37,373	D	
Common Stock	09/04/2019		M		10,293	A	\$9.57	47,666	D	
Common Stock	09/04/2019		M		3,264	A	\$24.65	50,930	D	
Common Stock	09/04/2019		M		1,853	A	\$33.35	52,783	D	
Common Stock	09/04/2019		S <sup>(1)</sup>		44,276	D	\$39.03 <sup>(2)</sup>	8,507	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Title
Stock Options (Right to Buy)	\$8.68	09/04/2019		M		6,835	(3)	02/14/2024	Common Stock	6,835	\$0	0	D	
Stock Options (Right to Buy)	\$10.36	09/04/2019		M		17,751	(4)	02/16/2025	Common Stock	17,751	\$0	0	D	
Stock Options (Right to Buy)	\$9.57	09/04/2019		M		10,293	(5)	02/15/2026	Common Stock	10,293	\$0	3,433	D	
Stock Options (Right to Buy)	\$24.65	09/04/2019		M		3,264	(6)	02/14/2027	Common Stock	3,264	\$0	3,265	D	
Stock Options (Right to Buy)	\$33.35	09/04/2019		M		1,853	(7)	02/14/2028	Common Stock	1,853	\$0	5,561	D	

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2019.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$38.48 to \$39.94, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. The stock options vested in four equal annual installments and were fully exercisable as of December 31, 2017.
4. The stock options vested in four equal annual installments and were fully exercisable as of December 31, 2018.
5. The stock options vested at the rate of 25% on each of December 31, 2016, 2017 and 2018 with the remainder of the stock options vesting on December 31, 2019; provided that the option holder remains in continuous service through the applicable vesting date.
6. The stock options vested at the rate of 25% on each of December 31, 2017 and 2018 with the remainder of the stock options vesting in equal amounts on each of December 31, 2019 and 2020; provided that the option holder remains in continuous service through the applicable vesting date.
7. The stock options vested at the rate of 25% on the first anniversary of the grant date with the remainder of the stock options vesting in equal amounts on the second, third and fourth anniversaries of the grant date; provided that the option holder remains in continuous service through the applicable vesting date.

**Remarks:**

/s/ Peter F. Ferola

09/06/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**